CRISPR-Cas-Based Genome Editing for Treating Human Diseases-Part A: Volume 208 | Agenda Bookshop Skip to content
Selected Colleen Hoover Books at €9.99c | In-store & Online
Selected Colleen Hoover Books at €9.99c | In-store & Online
Age Group_Uncategorized
Age Group_Uncategorized
automatic-update
B13=Vijay Singh
Category1=Non-Fiction
Category=PHVN
Category=PSB
Category=PSD
COP=United States
Delivery_Pre-order
Language_English
PA=Not yet available
Price_€100 and above
PS=Forthcoming
softlaunch

CRISPR-Cas-Based Genome Editing for Treating Human Diseases-Part A: Volume 208

English

CRISPR-Cas-Based Genome Editing for Treating Human Diseases-Part A, Volume 208 represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems are proven a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. CRISPR-Cas9 system is being used in microbial genome editing, mammalian genome editing, disease models, and more. It has shown potential in human disease treatment. However, it is not easy to find CRISPR-Cas systems genome editing in a single source. This volume offers CRISPR-Cas systems for human diseases, bacterial disease, gut microbiome editing, viral disease, protozoan disease, fungal disease, stem cell therapy, CRISPR in epigenetics, CRISPR in cancer, autoimmune and blood disorders. In addition, it highlights a number of aspects of the CRISPR-Cas systems that can help the basic understanding of students, researchers, clinicians, entrepreneurs, and stakeholders to perform their research with great interest. See more
Current price €126.34
Original price €132.99
Save 5%
Age Group_Uncategorizedautomatic-updateB13=Vijay SinghCategory1=Non-FictionCategory=PHVNCategory=PSBCategory=PSDCOP=United StatesDelivery_Pre-orderLanguage_EnglishPA=Not yet availablePrice_€100 and abovePS=Forthcomingsoftlaunch

Will deliver when available. Publication date 01 Oct 2024

Product Details
  • Dimensions: 152 x 229mm
  • Publication Date: 01 Oct 2024
  • Publisher: Elsevier Science Publishing Co Inc
  • Publication City/Country: United States
  • Language: English
  • ISBN13: 9780443315886

About

Dr Vijai Singh is a Professor and Dean (Research & Innovation) at School of Sciences Indrashil University Rajpur Mehsana Gujarat India. He was an Associate Professor in the Department of Biosciences School of Sciences Indrashil University Rajpur Mehsana Gujarat India. Prior this this he was an Assistant Professor in the Department of Biological Sciences and Biotechnology at the Institute of Advanced Research Gandhinagar India and also an Assistant Professor in the Department of Biotechnology at the Invertis University Bareilly India. Prior to that he was a Postdoctoral Fellow in the Synthetic Biology Group at the Institute of Systems and Synthetic Biology Paris France and School of Energy & Chemical Engineering at the Ulsan National Institute of Science and Technology Ulsan South Korea. He received his Ph.D. in Biotechnology from the National Bureau of Fish Genetic Resources Uttar Pradesh Technical University Lucknow India with a research focus on the development of molecular and immunoassays for diagnosis of Aeromonas hydrophila. His research interests are focused on building novel biosynthetic pathways for production of medically and industrially important biomolecules. Additionally his laboratory is working on CRISPR-Cas9 tools for genome editing. He has more than 11 years of research and teaching experience in synthetic biology metabolic engineering bioinformatics microbiology and industrial microbiology. He has published 100 articles 70 chapters 15 books and 3 patents. He serves as an associate editor editorial board member and reviewer of several peer-reviewed journals. He is also a member of the Board of Study and Academic Council of Indrashil University and is the Member Secretary of the Institutional Biosafety Committee (IBSC) at the same University.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept